Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Lymphoma, Follicular × palbociclib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 5 Pancreatic Neoplasms 2 Ovarian Neoplasms 2 Sarcoma 1 Prostatic Neoplasms 1 Neoplasms 1 Neoplasm Metastasis 1 Lymphoma, Follicular 1 Fallopian Tube Neoplasms 1 Estrogen Receptor Positive 1 Colorectal Neoplasms 1 Carcinoma, Endometrioid 1 COVID-19 1 Brain Neoplasms 1 Adenocarcinoma of Lung 1

Interventions

Rituximab 13 Cyclophosphamide 10 fludarabine phosphate 8 Peripheral Blood Stem Cell Transplantation 7 Radiotherapy 5 Whole-Body Irradiation 4 Vincristine 4 Prednisone 4 Lenalidomide 4 Etoposide 4 Doxorubicin 4 Cytarabine 4 Bendamustine Hydrochloride 4 tazemetostat 3 fludarabine 3 Mycophenolic Acid 3 Filgrastim 3 umbralisib 2 ublituximab 2 sargramostim 2 parsaclisib 2 ofatumumab 2 ibritumomab tiuxetan 2 duvelisib 2 Tacrolimus 2 Pentostatin 2 Pentetic Acid 2 Methotrexate 2 Melphalan 2 LFB-R603 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05371275 2022-11-07

CDK6COV

biotx.ai GmbH

Phase 2 Withdrawn

COVID-19, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡